Don Gabriel joins United BioSource Corp.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

DON GABRIEL joined the Global Clinical Development & Operations team of United BioSource Corp., a subsidiary of Express Scripts. Gabriel will direct UBC’s consultative services to pharmaceutical sponsors developing oncology therapies.

A bone marrow transplant physician, Gabriel held a long tenure at the University of North Carolina where he served as professor of medicine, associate chief of staff, assistant dean for clinical services, acting chief of medical oncology, and service chief liaison of the Division of Hematology/Oncology.

He has co-developed an optical laser-based technology used to identify and characterize suspended particles in the blood, including circulating tumor cells.

“Joining UBC gives me the opportunity to work with an organization that is using cutting edge clinical study design to search deep into the biochemistry of new molecules and help take those molecules to the next stage of development,” said Gabriel.

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login